Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) [1].
In Vivo, Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1].
In Vitro, Zevaquenabant can simultaneously inhibit CB1 receptors and inducible NOS in peripheral organs[1].
References:
[1]. Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.
In Vivo, Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1].
In Vitro, Zevaquenabant can simultaneously inhibit CB1 receptors and inducible NOS in peripheral organs[1].
References:
[1]. Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.